Premium
PTTG ‐1 (Securin) immunoexpression in meningiomas correlates with tumor grade and proliferation rate: potential use as a diagnostic marker of malignancy
Author(s) -
Iliadis Alexandros,
Virvili MariaAikaterini,
Flaris Nicolaos A.,
Pervana Stavroula,
Pazarli Elissabet,
Tripsianis Grigoris,
Grigoriou Maria E.,
Efstratiou Ioannis,
Kanakis Dimitrios N.
Publication year - 2018
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12825
Subject(s) - securin , proliferation marker , immunohistochemistry , mitotic index , medicine , ki 67 , malignancy , meningioma , oncology , proliferation index , pathology , cancer research , cancer , biology , mitosis , cell cycle , anaphase , microbiology and biotechnology
This study essentially aims to contribute to the immunohistochemical investigation of the use of pituitary tumor transforming gene (PTTG) as a marker of cell proliferation or advanced tumor grade in meningiomas of various WHO grades. In all, 51 cases were recovered in total, 21 Grade‐I, 23 Grade‐ II and 7 Grade‐ III meningiomas. Mitotic index ( MI ), Ki‐67/MiB‐1 positivity percentage and PTTG expression were analyzed in correlation to each other as well as to the tumor WHO grades. All three biomarkers showed a high diagnostic significance and a strong association with WHO grades. In comparison, PTTG expression was on a par with the other two indices, and performed very well regarding identification of advanced grade tumors. PTTG may be considered an important diagnostic tool and serve in the future as a novel prognosticator of the biological behavior of all grade meningiomas as well as a useful high‐risk patient selection tool.